Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study.

Cook NS, Tripathi P, Weiss O, Walda S, George AT, Bushell A.

Adv Ther. 2019 Apr;36(4):842-857. doi: 10.1007/s12325-019-00900-1. Epub 2019 Mar 11.

PMID:
30859499
2.

A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials.

Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scottá C, Hope A, Fisher C, Hilton R, Game D, Harden P, Bushell A, Wood K, Lechler RI, Lombardi G.

Mol Ther Methods Clin Dev. 2018 Jan 31;8:198-209. doi: 10.1016/j.omtm.2018.01.006. eCollection 2018 Mar 16.

3.

Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry.

Juvet SC, Moshkelgosha S, Sanderson S, Hester J, Wood KJ, Bushell A.

J Vis Exp. 2017 Apr 19;(122). doi: 10.3791/55283.

4.

Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance.

Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, Fehr T, Cippà PE.

Front Immunol. 2016 Mar 1;7:73. doi: 10.3389/fimmu.2016.00073. eCollection 2016.

5.

Quantification of CD4(+) T Cell Alloreactivity and Its Control by Regulatory T Cells Using Time-Lapse Microscopy and Immune Synapse Detection.

Juvet SC, Sanderson S, Hester J, Wood KJ, Bushell A.

Am J Transplant. 2016 May;16(5):1394-407. doi: 10.1111/ajt.13607. Epub 2016 Jan 29.

6.

Hurdles in therapy with regulatory T cells.

Trzonkowski P, Bacchetta R, Battaglia M, Berglund D, Bohnenkamp HR, ten Brinke A, Bushell A, Cools N, Geissler EK, Gregori S, Marieke van Ham S, Hilkens C, Hutchinson JA, Lombardi G, Madrigal JA, Marek-Trzonkowska N, Martinez-Caceres EM, Roncarolo MG, Sanchez-Ramon S, Saudemont A, Sawitzki B.

Sci Transl Med. 2015 Sep 9;7(304):304ps18. doi: 10.1126/scitranslmed.aaa7721. Review.

PMID:
26355029
7.

Regulatory T cells: first steps of clinical application in solid organ transplantation.

van der Net JB, Bushell A, Wood KJ, Harden PN.

Transpl Int. 2016 Jan;29(1):3-11. doi: 10.1111/tri.12608. Epub 2015 Jun 3. Review.

8.

Varying degrees of ventricular unloading in the heterotopic rat heart transplant model demonstrated by magnetic resonance imaging.

Carr CA, Ball D, Tyler DJ, Bushell A, Sykes A, Clarke K, Evans RD.

Int J Biomed Sci. 2014 Dec;10(4):223-8.

9.

Alloreactive regulatory T cells generated with retinoic acid prevent skin allograft rejection.

Moore C, Tejon G, Fuentes C, Hidalgo Y, Bono MR, Maldonado P, Fernandez R, Wood KJ, Fierro JA, Rosemblatt M, Sauma D, Bushell A.

Eur J Immunol. 2015 Feb;45(2):452-63. doi: 10.1002/eji.201444743. Epub 2014 Dec 2.

10.

Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning.

Juvet SC, Whatcott AG, Bushell AR, Wood KJ.

Am J Transplant. 2014 Apr;14(4):750-63. doi: 10.1111/ajt.12647. Epub 2014 Mar 4. Review.

11.

Induction of transplantation tolerance through regulatory cells: from mice to men.

Ferrer IR, Hester J, Bushell A, Wood KJ.

Immunol Rev. 2014 Mar;258(1):102-16. doi: 10.1111/imr.12158. Review.

PMID:
24517428
12.

Single cell tracking of gadolinium labeled CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry.

Managh AJ, Edwards SL, Bushell A, Wood KJ, Geissler EK, Hutchinson JA, Hutchinson RW, Reid HJ, Sharp BL.

Anal Chem. 2013 Nov 19;85(22):10627-34. doi: 10.1021/ac4022715. Epub 2013 Oct 3.

PMID:
24080112
13.

Targeting apoptosis to induce stable mixed hematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice.

Cippà PE, Gabriel SS, Chen J, Bardwell PD, Bushell A, Guimezanes A, Kraus AK, Wekerle T, Wüthrich RP, Fehr T.

Blood. 2013 Aug 29;122(9):1669-77. doi: 10.1182/blood-2012-09-453944. Epub 2013 Jul 18.

14.

Nanoporous organic polymer/cage composite membranes.

Bushell AF, Budd PM, Attfield MP, Jones JT, Hasell T, Cooper AI, Bernardo P, Bazzarelli F, Clarizia G, Jansen JC.

Angew Chem Int Ed Engl. 2013 Jan 21;52(4):1253-6. doi: 10.1002/anie.201206339. Epub 2012 Dec 6. No abstract available.

15.

Regulatory immune cells in transplantation.

Wood KJ, Bushell A, Hester J.

Nat Rev Immunol. 2012 May 25;12(6):417-30. doi: 10.1038/nri3227. Review.

PMID:
22627860
16.

Moving to tolerance: clinical application of T regulatory cells.

McMurchy AN, Bushell A, Levings MK, Wood KJ.

Semin Immunol. 2011 Aug;23(4):304-13. doi: 10.1016/j.smim.2011.04.001. Epub 2011 May 28. Review.

17.

Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection.

Feng G, Nadig SN, Bäckdahl L, Beck S, Francis RS, Schiopu A, Whatcott A, Wood KJ, Bushell A.

Sci Transl Med. 2011 May 18;3(83):83ra40. doi: 10.1126/scitranslmed.3002099.

18.

Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells.

Wood KJ, Bushell A, Jones ND.

Immunol Rev. 2011 May;241(1):119-32. doi: 10.1111/j.1600-065X.2011.01013.x. Review.

PMID:
21488894
19.

Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells.

Francis RS, Feng G, Tha-In T, Lyons IS, Wood KJ, Bushell A.

Eur J Immunol. 2011 Mar;41(3):726-38. doi: 10.1002/eji.201040509. Epub 2011 Jan 17.

20.

Regulatory T cell enrichment by IFN-γ conditioning.

Feng G, Wood KJ, Bushell A.

Methods Mol Biol. 2011;677:281-301. doi: 10.1007/978-1-60761-869-0_20.

PMID:
20941618
21.

CD4+ regulatory T cells generated in vitro with IFN-{gamma} and allogeneic APC inhibit transplant arteriosclerosis.

Warnecke G, Feng G, Goto R, Nadig SN, Francis R, Wood KJ, Bushell A.

Am J Pathol. 2010 Jul;177(1):464-72. doi: 10.2353/ajpath.2010.090292. Epub 2010 May 14.

22.

Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells.

Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ.

Transplantation. 2010 Jun 27;89(12):1446-55. doi: 10.1097/TP.0b013e3181dd6bf1.

PMID:
20463648
23.

Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation.

Ding Y, Bushell A, Wood KJ.

Transplantation. 2010 Feb 15;89(3):270-3. doi: 10.1097/TP.0b013e3181c6ffbe.

24.

The discovery of immunological tolerance: now more than just a laboratory solution.

Wood KJ, Bushell AR, Jones ND.

J Immunol. 2010 Jan 1;184(1):3-4. doi: 10.4049/jimmunol.0990108. No abstract available.

25.

Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9.

Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ.

Diabetes. 2009 Aug;58(8):1797-806. doi: 10.2337/db09-0317. Epub 2009 Jun 9.

26.

Donor reactive regulatory T cells.

Feng G, Chan T, Wood KJ, Bushell A.

Curr Opin Organ Transplant. 2009 Aug;14(4):432-8. doi: 10.1097/MOT.0b013e32832c58f1. Review.

PMID:
19448539
27.

Neutralizing interleukin-4 prevents transplant arteriosclerosis mediated by indirect pathway T cells under CD40-CD154 costimulation blockade.

Spriewald BM, Ensminger SM, Bushell A, Wood KJ.

Transplantation. 2008 Dec 15;86(11):1615-21. doi: 10.1097/TP.0b013e31818bbd3a.

PMID:
19077898
28.

Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation.

Bäckdahl L, Bushell A, Beck S.

Int J Biochem Cell Biol. 2009 Jan;41(1):176-84. doi: 10.1016/j.biocel.2008.08.023. Epub 2008 Aug 26. Review.

PMID:
18793748
29.

Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells.

Feng G, Gao W, Strom TB, Oukka M, Francis RS, Wood KJ, Bushell A.

Eur J Immunol. 2008 Sep;38(9):2512-27. doi: 10.1002/eji.200838411.

30.

Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy.

Feng G, Wood KJ, Bushell A.

Transplantation. 2008 Aug 27;86(4):578-89. doi: 10.1097/TP.0b013e3181806a60.

PMID:
18724229
31.

Investigation into the onset and progression of transplant arteriosclerosis in a mice aortic retransplantation model.

Steger U, Ensminger S, Bushell A, Wood KJ.

Microsurgery. 2008;28(3):182-6. doi: 10.1002/micr.20477.

PMID:
18253942
32.

Dependency of the trans vivo delayed type hypersensitivity response on the action of regulatory T cells: implications for monitoring transplant tolerance.

Warnecke G, Chapman SJ, Bushell A, Hernandez-Fuentes M, Wood KJ.

Transplantation. 2007 Aug 15;84(3):392-9.

PMID:
17700166
33.

Interferon gamma: friend or foe?

Wood KJ, Feng G, Wei B, Sawitzki B, Bushell AR.

Transplantation. 2007 Jul 15;84(1 Suppl):S4-5.

PMID:
17632413
34.

Regulation of transplant arteriosclerosis by CD25+CD4+ T cells generated to alloantigen in vivo.

Warnecke G, Bushell A, Nadig SN, Wood KJ.

Transplantation. 2007 Jun 15;83(11):1459-65.

PMID:
17565319
35.

Functional dichotomy of NK cells in organ transplantation.

Tha-In T, Luo S, Bushell AR, Wood KJ.

Expert Rev Clin Immunol. 2007 May;3(3):261-6. doi: 10.1586/1744666X.3.3.261.

PMID:
20477669
36.

Identification of gene markers for the prediction of allograft rejection or permanent acceptance.

Sawitzki B, Bushell A, Steger U, Jones N, Risch K, Siepert A, Lehmann M, Schmitt-Knosalla I, Vogt K, Gebuhr I, Wood K, Volk HD.

Am J Transplant. 2007 May;7(5):1091-102.

38.

CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection.

Steger U, Kingsley CI, Karim M, Bushell AR, Wood KJ.

Transplantation. 2006 Nov 15;82(9):1202-9.

PMID:
17102772
39.
41.

A simple method to cure established tumors by inflammatory killing of normal cells.

Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG.

Nat Biotechnol. 2004 Sep;22(9):1125-32. Epub 2004 Aug 1.

42.

Permanent survival of organ transplants without immunosuppression: Experimental approaches and possibilities for tolerance induction in clinical transplantation.

Bushell A, Wood KJ.

Expert Rev Mol Med. 1999 Oct 29;1999:1-31. doi: 10.1017/S1462399499001179. No abstract available.

PMID:
14987354
43.

Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process.

Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ.

J Immunol. 2004 Jan 15;172(2):923-8.

44.

Regulatory cells in transplantation.

Wood KJ, Ushigome H, Karim M, Bushell A, Hori S, Sakaguchi S.

Novartis Found Symp. 2003;252:177-88; discussion 188-93, 203-10. Review.

PMID:
14609219
45.
46.
47.

Ischaemic preconditioning of skeletal muscle 2. Investigation of the potential mechanisms involved.

Bushell AJ, Klenerman L, Davies H, Grierson I, McArdle A, Jackson MJ.

J Bone Joint Surg Br. 2002 Nov;84(8):1189-93.

PMID:
12463669
48.

Ischaemic preconditioning of skeletal muscle. 1. Protection against the structural changes induced by ischaemia/reperfusion injury.

Bushell AJ, Klenerman L, Taylor S, Davies H, Grierson I, Helliwell TR, Jackson MJ.

J Bone Joint Surg Br. 2002 Nov;84(8):1184-8.

PMID:
12463668
49.

Regulatory T cells in transplantation.

Karim M, Bushell AR, Wood KJ.

Curr Opin Immunol. 2002 Oct;14(5):584-91. Review.

PMID:
12183157
50.

TGF-beta and graft vasculopathy: where to from here?

Bushell A.

Transplantation. 2002 May 27;73(10):1534-6. No abstract available.

PMID:
12042635

Supplemental Content

Loading ...
Support Center